ESMO 2023 Insights: "Phase 3 Randomized EMBARK Study - Enzalutamide/Placebo + Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Stephen Freedland
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Stephen Freedland
Disclaimer: This video was recorded prior to FDA approval of enzalutamide on November 17, 2023 for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
Comments 0
Login to view comments.
Click here to Login
